Dr. Toby Maher
will be presenting data results from the Phase 2 CANAL trial in IPF
chronic cough at American Cough Conference
NEW
HAVEN, Conn., May 30, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for difficult
to treat patients with chronic cough in idiopathic pulmonary
fibrosis (IPF), other chronic cough indications, and prurigo
nodularis, today announced senior management will attend and
participate in the following conferences in June. In addition,
Toby Maher, MD, Professor of
Medicine and Director of Interstitial Lung Disease at Keck School
of Medicine, University of Southern
California, will be presenting data from Trevi's Phase 2
CANAL trial in IPF chronic cough at the American Cough Conference
on June 9th.
![Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.) Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)](https://mma.prnewswire.com/media/1504281/Trevi_Therapeutics_Logo.jpg)
Yale Innovation Summit (May
31-June 1)
Title: Trevi Therapeutics Yale Innovation Summit
Presentation
Presenters: Jennifer
Good, President and CEO of Trevi Therapeutics,
Farrell Simon, Chief Commercial Officer
of Trevi Therapeutics, and Peter Dicpinigaitis, MD,
Professor of Medicine, Albert Einstein College of
Medicine, Division of Critical Care
Medicine, Montefiore Medical Center,
Director, Montefiore Cough Center and Editor-in-Chief,
LUNG
Presentation: Thursday, June 1, 10:30
AM-12 PM ET
Registration: Investors and analysts can register to attend
the in-person event by using the following
link: https://ventures.yale.edu/yale-innovation-summit
BIO International Convention (June
5-8)
Title: Trevi Therapeutics Corporate Presentation
Presenter: Jennifer Good,
President and CEO
Presentation: Tuesday, June
6th, 4:45 PM ET
Partnering Representatives: Jennifer
Good, President and CEO, and Farrell Simon, Chief Commercial
Officer
Registration: Register to attend the in-person event by
clicking here.
American Cough Conference (June
9-10)
Title: Nalbuphine extended release treatment achieved rapid
and sustained reduction in reported cough frequency in patients
with idiopathic pulmonary fibrosis
Presenter: Toby Maher, MD, Professor of Medicine and
Director of Interstitial Lung Disease at Keck School of
Medicine, University of Southern
California
Presentation: Friday, June
9th, 3:40 PM ET
Title: Development Plans for Nalbuphine ER in Cough
Presenter: Thomas Sciascia,
MD, Chief Scientific Officer
Presentation: Saturday, June
10th, 11:25 AM ET
Registration: Health care professionals can register to
attend the in-person American Cough Conference by clicking
here.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for difficult to treat patients with chronic cough
in idiopathic pulmonary fibrosis (IPF), other chronic cough
indications, and prurigo nodularis. Haduvio is a dual ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that works both
centrally as well as peripherally in the lungs and has the
potential for a synergistic anti-tussive effect to treat chronic
cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. There are no approved therapies for the treatment of chronic
cough in IPF and current treatment options provide minimal relief
to patients. In IPF, chronic cough may lead to worsening fibrosis
and may be associated with a higher risk of progression, death, or
need for lung transplant.
Parenteral nalbuphine is not scheduled by the US DEA. Trevi
intends to propose Haduvio as the trade name for nalbuphine ER. Its
safety and efficacy have not been evaluated by any regulatory
authority.
For more information,
visit www.TreviTherapeutics.com and follow Trevi
on Twitter and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-june-conferences-301836195.html
SOURCE Trevi Therapeutics, Inc.